EPHA2 and glioblastoma: Clinical trials of VEGF-targeted therapy for GBM have shown upregulated serum levels of ANGPT2, EphA2, and FGF2 in the refractory period [17, 20, 28], while changes in the expression level of PLGF were controversial [8, 10, 21, 29].